BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26138905)

  • 1. Transient myeloproliferative disorder with partial trisomy 21.
    Takahashi T; Inoue A; Yoshimoto J; Kanamitsu K; Taki T; Imada M; Yamada M; Ninomiya S; Toki T; Terui K; Ito E; Shimada A
    Pediatr Blood Cancer; 2015 Nov; 62(11):2021-4. PubMed ID: 26138905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
    Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
    PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
    Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
    J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
    Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
    Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
    Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
    Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
    Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
    Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.
    Tsai MH; Hou JW; Yang CP; Yang PH; Chu SM; Hsu JF; Chiang MC; Huang HR
    Indian J Pediatr; 2011 Jul; 78(7):826-32. PubMed ID: 21287369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
    Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
    Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease.
    Bertrums EJ; Buijs A; van Grotel M; Dors N; de Rooij JD; de Haas V; Hopman S; Jongmans MC; Zwaan CM; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
    Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
    An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital GATA1-mutated myeloproliferative disorder in trisomy 21 complicated by placental fetal thrombotic vasculopathy.
    Loh TJ; Lian DW; Iyer P; Lam JC; Kuick CH; Aung AC; Chang KT
    Hum Pathol; 2014 Nov; 45(11):2364-7. PubMed ID: 25248574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
    Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
    Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities.
    Banno K; Omori S; Hirata K; Nawa N; Nakagawa N; Nishimura K; Ohtaka M; Nakanishi M; Sakuma T; Yamamoto T; Toki T; Ito E; Yamamoto T; Kokubu C; Takeda J; Taniguchi H; Arahori H; Wada K; Kitabatake Y; Ozono K
    Cell Rep; 2016 May; 15(6):1228-41. PubMed ID: 27134169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome.
    Greber-Platzer S; Schatzmann-Turhani D; Wollenek G; Lubec G
    Biochem Biophys Res Commun; 1999 Jan; 254(2):395-9. PubMed ID: 9918849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient myeloproliferative disorder with trisomy 12.
    Basu B; Gupta V
    Pediatr Hematol Oncol; 2010 Apr; 27(3):233-6. PubMed ID: 20367267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proto-oncogene ERG in megakaryoblastic leukemias.
    Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
    Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.